TREATMENT OPTIONS

The goal of treatment for hemophilia A is to replace the missing clotting factor (factor VIII) in order to stop and prevent bleeding.¹

Treatment for Moderate and Severe Hemophilia A*^1,2

The main treatment for moderate and severe hemophilia A is factor VIII replacement therapy. There are two types of factor VIII products: human plasma-derived factor VIII and recombinant factor VIII. Both of these options are effective and a healthcare provider can help the patient decide which option is best.

Factor VIII replacement therapy involves infusing the missing clotting factor directly into the bloodstream. Factor VIII infusions may be given¹:

As needed to stop bleeding when it occurs (on-demand therapy)
On a regular basis to prevent bleeding (prophylactic therapy)

To learn about factor VIII replacement therapy with Koāte-DVI, please see About Koāte-DVI. Ask your doctor if Koāte-DVI is right for you.

*Mild hemophilia may be treated with an injection of desmopressin. Desmopressin stimulates factor VIII production in people whose bodies can still make some factor VIII.²

Important Safety Information

Koāte-DVI is indicated for the treatment of classical hemophilia (hemophilia A) in which there is a demonstrated deficiency of activity of the plasma clotting factor, factor VIII.

Allergic-type reactions may result from the administration of Antihemophilic Factor (Human) preparations. In clinical studies, adverse reactions included tingling in the arm, ear, and face, blurred vision, headache, nausea, stomach ache, and jittery feeling.

Koāte-DVI is made from human plasma. Products made from human plasma may contain infectious agents, such as viruses, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent that can cause disease. There is also the possibility that unknown infectious agents may be present in such products.

Hepatitis B vaccination is essential for patients with hemophilia A; vaccination is recommended at birth or at the time of diagnosis. Hepatitis A vaccination is also recommended for hemophilia patients who are hepatitis A seronegative.

Please see Koate-DVI full Prescribing Information for complete prescribing details.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

References: 1. Dargaud Y, Negrier C. Haemophilia therapies. Expert Opin Biol Ther. 2007;7:651–663. 2. National Hemophilia Foundation. MASAC recommendation #187. MASAC recommendations concerning the treatment of hemophilia and other bleeding disorders. http://www.hemophilia.org/. Accessed January 28, 2009.

TREATMENT OPTIONS

Treatment for Moderate and Severe Hemophilia A*1,2

Important Safety Information

Treatment for Moderate and Severe Hemophilia A*^1,2